[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2627 followers Created: 2025-07-10 12:32:27 UTC $ABOS Acumen Pharmaceuticals to share findings on cost savings from pTau217 screening in the Phase X ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at AAIC 2025. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$abos](/topic/$abos) [Post Link](https://x.com/OzmosiHealth/status/1943287200348799391)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2627 followers
Created: 2025-07-10 12:32:27 UTC
$ABOS Acumen Pharmaceuticals to share findings on cost savings from pTau217 screening in the Phase X ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at AAIC 2025.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1943287200348799391